News | May 05, 2014

First Rotational IMRT Treatment Delivered at Europe Hospitals

May 5, 2014 — The first clinical mARC treatment, planned with RaySearch’s treatment planning system RayStation, has been delivered at Europe Hospitals in Brussels, Belgium. mARC (Modulated Arc) is a type of rotational IMRT treatment carried out with Siemens Artiste linear accelerators, where the beam is kept turned on as the gantry rotates around the patient. The concept enables as high treatment precision as with ordinary IMRT but with significantly faster delivery times.

Europe Hospitals is the largest private hospital group in Brussels with 716 stay-in beds and 200 one-day beds. They employ about 300 medical doctors and 2,000 staff members spread over two sites. Brussels Europe Hospitals run a private radiotherapy and oncology department. The external beam radiotherapy department is fully equipped for modern external beam and HDR-brachytherapy treatments.

“We acquired RayStation in 2013 based on the breadth of technology including support of rotational IMRT for all types of linear accelerators, the high speed of planning and dose computation, the robustness of optimization and the ease of analysis. Now we have implemented mARC or rotational IMRT on the Siemens Artiste linear accelerators clinically, and on April 17 the first patient worldwide received an mARC treatment that was planned in RayStation,” said Dr. Carl Salembier, head of the Radiation Oncology department at Brussels Europe Hospitals.

Alex Rijnders, chief medical physicist at Brussels Europe Hospitals, added: "We are happy that we can offer our patients this advanced treatment modality. Thanks to the powerful capabilities of RayStation, treatment planning turned out easy and efficient, leading to optimal solutions and high plan quality. We are looking forward to further collaboration with RaySearch in exploring the possibilities offered by the mARC treatment modality, such as hybrid treatments."

For more information: www.raysearchlabs.com

Related Content

New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at
Improved Imaging for Prostate Cancer Could Lead to More Effective Treatment

The picture shows that time series signal is extracted from a series of ultrasound frames for classification. Each patch across a number of frames inside the prostate is classified into either cancerous or normal tissue. The image at the lower right corner shows the overall result for those frames. Image courtesy of Pingkun Yan and researchers from NIH, University of British Columbia and Queens University.

News | Ultrasound Imaging | May 28, 2019
Engineers at Rensselaer Polytechnic Institute are working to improve imaging methods in order to make medicine more...